Skip to Main Content

In April, endocrinologist Calvin Wu described how his company, Steady Health, was making use of the flowing stream of data from continuous glucose monitors to help patients with type 1 diabetes manage their blood glucose and avoid dangerous complications. That effort extended to some patients with type 2 diabetes, but he drew the line there.

“I think there may very well be a role for CGM down the road as more of a preventative kind of use case,” said Wu. “But I think the challenge here is that the evidence for that right now is fairly light.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment